IcoSema for Type 2 Diabetes
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial will test a new weekly injection called IcoSema, which combines two drugs, in people with type 2 diabetes. It aims to see if IcoSema can control blood sugar better than the current daily treatments. Participants will receive either IcoSema or the standard daily injections. The study will take place over several months, and participants will wear a sensor to monitor their blood sugar levels.
Who Is on the Research Team?
Clinical Transparency (dept. 1452)
Principal Investigator
Novo Nordisk A/S
Are You a Good Fit for This Trial?
Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either IcoSema once weekly or insulin glargine daily with insulin aspart for 52 weeks
Monitoring
Participants wear a continuous glucose monitoring sensor for 8 weeks at the beginning and 4 weeks at the end of the study
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- IcoSema
- Insulin aspart
- Insulin glargine
Find a Clinic Near You
Who Is Running the Clinical Trial?
Novo Nordisk A/S
Lead Sponsor
Lars Fruergaard Jørgensen
Novo Nordisk A/S
Chief Executive Officer since 2017
MSc in Finance and Business Administration, Aarhus School of Business, Aarhus University, Denmark
Martin Holst Lange
Novo Nordisk A/S
Chief Medical Officer since 2021
MD from University of Copenhagen